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PROBLEM 
Estrogen receptor positive (ER+) and estrogen receptor negative (ER-) are two major types of breast 
cancer.  For women with ER+ positive breast cancer, patients are treated with the antiestrogenic 
compounds, tamoxifen or faslodex for five years, immediately after surgical resection of tumors.  
Unfortunately, 30-40% of these patients will develop resistance to endocrine therapy.  Our recent 
study has shown that the Hedgehog (Hhg) signaling pathway plays a significant role in endocrine 
resistance and that the aberrantly activated transcription factor, GLI-1, is vital to the development of 
resistance. However, not much is known about the GLI-1 target genes that might contribute to 
endocrine resistance. Our goal is to determine novel target genes of GLI-1 and determine how these 
genes promote endocrine therapy resistance. 
 
BACKGROUND 
 
Breast Cancer 
 
 Breast cancer is the most prevalent and second most deadly cancer among women in the 
United States.1 While breast cancer incidence has increased over the past 30 years partly because of 
increased screening programs and therefore earlier and efficient detection, breast cancer mortality has 
declined.2 There are four subtypes of breast cancer: Luminal A, Luminal B, HER2 enriched (Human 
Epidermal Growth Factor-2), and triple negative. Each subtype is classified by the presence of four 
molecular markers: estrogen receptor (ER), progesterone receptor (PR), HER2, and Ki-67, a 
proliferative marker (Fig.1).3 
The involvement of the hormone estrogen in breast cancer progression has been known since 
1896, when removal of the ovaries, the source of endogenous estrogen, led to the remission of 
metastatic breast cancer in some women.4 The active form of estrogen, 17β-estradiol (E2), exerts its  
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biological effect upon binding to its receptor, estrogen receptor alpha (ERα). Following activation, 
the E2/ER complex acts as a transcription factor and activates several downstream target genes upon 
binding to a palindromic 13 base pair consensus sequence: 5’-GGTACnnnTGTTCT-3’.5   Binding of 
E2 to ER also activates several signaling pathways leading to cell proliferation. It is well known that 
the activation of ERα results in cellular proliferation through genomic and non-genomic interactions.6 
Inhibiting the function of estrogen and ERα has been the cornerstone of therapy for women with 
estrogen receptor positive (ER+) breast cancer since the 1960s. 
 
Estrogen Receptor Positive Breast Cancer Therapies 
 Tamoxifen (TAM) has been the first line of therapy for patients with ER+ breast cancer for 
over 40 years. TAM is a selective estrogen receptor modulator (SERM) where binding to ER, inhibits 
binding and activation of ER by 17β-estradiol. Women with ER+ breast cancer today undergo 
adjuvant therapy constituting surgical resection of the tumor followed by endocrine therapy. Therapy 
with TAM following surgery has been very effective. TAM treatment for 5 years following surgery 
resulted in a 51% reduction in recurrence and 28% reduction in cancer-related deaths. However, 
treatment with endocrine therapy for more than 5 years can result in endometrial cancer.2 An 
alternative commonly used non-steroidal anti-estrogenic compound is faslodex (FAS). Faslodex is a 
selective estrogen receptor downregulator (SERD) that is also used to treat patients with ER+ breast 
Subtype	   Characteristics	  
Luminal	  A	   ER+,	  PR+,	  HER2-­‐	  (low	  Ki-­‐67)	  
Luminal	  B	   ER+,	  PR+,	  HER2-­‐	  (high	  Ki-­‐67)	  
Triple	  Negative	   ER-­‐,	  PR-­‐,	  HER2-­‐	  
HER2	  Enriched	   ER-­‐,	  PR-­‐,	  HER2+	  
Figure 1. Clinical subtypes of breast cancer are classified by the presence of 
estrogen receptor (ER), progesterone receptor (PR), HER2, and the proliferative 
marker, Ki67. 	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cancer. FAS binds to ER with high affinity and inhibits ER function through a mechanism that results 
in its nuclear export and degradation.2 It is important to note that patients with Luminal A and 
Luminal B breast cancer are treated with endocrine therapies as they express ER (Fig. 1). As 30-40% 
of women with ER+ breast cancer develop resistance to endocrine therapy, it important to study what 
contributes to this resistance. Recent work in our laboratory demonstrated that aberrant activation of 
sonic hedgehog pathway promotes development of resistance to tamoxifen.7 
 
The Hedgehog Pathway  
 The name hedgehog pathway was coined when scientists mutated the hedgehog (Hh) gene in 
Drosophila melanogaster embryos and observed that the embryos developed spiked-shaped 
projections, resembling the spikes of a hedgehog. In canonical hedgehog signaling, the pathway is 
regulated by one or more of three hedgehog ligands: Indian hedgehog (Ihh), desert hedgehog (Dhh) 
and sonic hedgehog (Shh). When the pathway is inactive, the hedgehog receptor, Patched (PTCH) 
inhibits the G-protein coupled receptor, Smoothend (SMO). However, upon binding of the ligand to 
PTCH, SMO is no longer inhibited and migrates to the cilium. This leads to activation of the Glioma-
associated oncoproteins, the GLI family of transcription factors. Once activated, GLI proteins migrate 
to the nucleus and exert their regulatory effects on the genome. The family is made up of three zinc-
fingered transcription factors: GLI-1, GLI-2, and GLI-3. GLI-1 is a known activator; GLI-3 is a 
known repressor; while GLI-2 can behave as both an activator and repressor of transcription.8  
6	  	  
The hedgehog pathway is active during embryogenesis and is responsible for body plan 
development and segmentation. During adulthood, the pathway remains mostly silent but its aberrant 
activation has been observed in several types of cancer including: basal cell carcinoma, 
medulloblastoma, glioblastoma, chronic lymphoid leukemia, pancreatic cancer, and breast cancer.9 
The hedgehog pathway can be activated in ligand-independent manner. This is caused by inactivating 
mutations of PTCH or activating mutations of SMO, leading to overall activation of SMO and GLI 
proteins.9 Ligand-independent activation of the hedgehog pathway can also occur through cross-talk 
with multiple signaling pathways and therefore dual inhibition of both hedgehog and EGFR, 
JAK/STAT, or PI3K pathways are currently underway in clinical trials.10  Ligand-dependent 
activation of hedgehog signaling can occur in an autocrine manner where the tumors secreting the 
hedgehog ligand act upon themself, thereby stimulating the growth of tumor cells.11 Studies also 
show that paracrine signaling can activate the hedgehog pathway in tumor cells where secretion of 
Figure 2. Canonical hedgehog signaling. A) Hedgehog signaling is inactive in the absence of the 
hedgehog ligand. PTCH inhibits SMO. B) Hedgehog signaling is active in the presence of the 
ligand. PTCH no longer inhibits SMO. SMO migrates to the cilium where it activates GLI 
transcription factors. GLI then migrates to the nucleus, activating or repressing target genes. 
Figure from: Unraveling the therapeutic potential of the Hedgehog pathway in cancer. Nature 
Medicine. 2013; 19; 1410-1422.  
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hedgehog ligands from the surrounding tumor microenvironment acts upon the tumor cells and vice 
versa.12  
Activation of the hedgehog pathway promotes tumor metastasis through upregulation of genes 
associated with epithelial to mesenchymal transition (EMT) such as SNAI1, SNAI2, TWIST2 and 
FOXC2.13 EMT is a process where tumors begin to lose their cell-adhesion capability. Following 
EMT, tumor cells gain migratory and invasive properties, allowing them to metastasize to other parts 
of the body. One study showed that EMT could be inhibited in prostate cancer stem cells in vivo by 
treating mice with the SMO inhibitor, Erismodegib.14 Targeting the hedgehog pathway could 
therefore be a valuable strategy to inhibit metastasis.  
There is also some evidence that the hedgehog pathway is involved in the maintenance of 
cancer stems cells (CSCs). Cancer stem cells are a small subpopulation of cancer cells that are 
implicated in tumor recurrence. CSCs are functionally defined by their self-renewal capability, their 
ability to differentiate, and their tumorgenicity (their ability to form tumors from a relatively few 
number of cells when implanted in mice). Importantly, the hedgehog proteins PTCH, GLI-1 and GLI-
2 are present in breast cancer stem/progenitor cells. These genes are downregulated when these cells 
were induced to differentiate. In addition, inhibition of hedgehog signaling components reduced 
mammosphere formation, indicating that the hedgehog pathway may be involved in the self-renewal 
capability of breast cancer stem cells.15 
 
The Hedgehog Pathway & Drug Resistance  
 A major problem in cancer therapy is the development of resistance to drug therapies. Multi-
drug resistance (MDR) occurs when cancer cells become resistant to several drugs with different 
molecular structures. Several studies implicate role of hedgehog pathway activation to the 
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development of drug resistance in cancer. For example, GLI-1, directly activates several ATP 
Binding Cassette (ABC) transporters including ABCG2 and ABCB1 which mediate the efflux of 
several chemotherapeutic agents such as miloxantrone, daunorubicin, and doxorubicin in breast 
cancer.16 Hedgehog pathway mediated activation of ABCG2 has also been associated with radiation 
resistance in pediatric medulloblastoma.17 Hedgehog signaling also mediated resistance to anti-EGFR 
therapies in head and neck cancer.18 Furthermore, CSCs are generally resistant to therapies and often 
express these ABC transporters19.  It is important to note that these ABC transporters have not been 
implicated in TAM or FAS transport in cancer cells. 
 
Non-canonical Hedgehog Signaling and Endocrine Resistance 
Recent studies in our laboratory demonstrated that the PI3K/AKT pathway plays a key role in 
upregulation of the hedgehog pathway by stabilizing SMO and GLI-1 proteins, and conferring 
resistance to tamoxifen. Glycogen synthase kinase 3-beta (GSK3β) remains in its active form and 
phosphorylates SMO and GLI-1 when the PI3K pathway is inactive.  This promotes proteasomal 
degradation of the two key Hedgehog signaling proteins. However, in tamoxifen resistant MCF7 cells, 
phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) activates the serine-threonine protein kinase, 
AKT. Following activation, AKT inhibits GSK3β, and prevents phosphorylation and subsequent 
degradation of SMO and GLI-1. This promotes the non-canonical activation of the Hhg signaling 
pathway (Fig. 3). 
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Si-RNA knockdown of hedgehog genes, SMO and GLI-1, in tamoxifen resistant cells 
markedly reduced their sensitivity to tamoxifen in vitro. Treatment of mice harboring tamoxifen-
resistance xenografts with Vismodegib (GDC-0449, Genentech) an inhibitor of SMO, inhibited the 
growth of these xenografts, suggesting that the hedgehog pathway is vital for growth of the endocrine 
resistant xenografts. In addition, high GLI-1 protein level inversely correlated with overall survival 
and disease free survival in primary human breast tumors .7 Our previous work elucidated the 
importance of GLI-1 in development of resistance to endocrine therapy. It is therefore important to 
identify the GLI-1 target genes and study their functional significance in the development of anti-
estrogen resistance. 
 
Hedgehog Targeted Therapies 
 Vismodegib is the only clinically approved SMO inhibitor that is used currently to treat 
patients with basal cell carcinoma. Other SMO inhibitors such as Sonidegib and BMS-833923 are in 
	  
Figure 3. PI3K activation stabilizes SMO and GLI-1 leading to hedgehog pathway activation. A) 
When PI3K is inactive, GSK3β phosphorylates SMO and GLI-1, designating these proteins for 
protesomal degradation. B) When PI3K is active, GSK3β is inhibited. SMO and GLI-1 remain 
active allowing GLI-1 to transcriptionally activate genes.	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clinical trials.10 In addition to SMO inhibitors, a screen of several small molecule inhibitory 
compounds targeting GLI-1 led to identification of GANT-61 and GANT58.20  However the high 
toxicity of these compounds prohibits them from being used in clinical trials.  Because the hedgehog 
pathway is often activated with other signaling pathways, several studies are now focusing on treating 
cancer patients with multiple inhibitors for better outcome.10 
 
Solute-like Carrier Family 39 Member 6 (SLC-39A6) 
 Our gene expression analysis identified SLC-39A6 as a putative target of GLI-1 that could be 
a mediator of TAM or FAS sensitivity in breast cancer cells. SLC-39A6 is a zinc-influx transporter 
protein located on the cell membrane.21 Knockdown of SLC-39A6 in T47D breast cancer cells 
reduced E-cadherin expression while increasing vimentin expression, indicating that SLC-39A6 may 
play a tumor suppressor role by inhibiting EMT. In addition, SLC-39A6 depletion was shown to 
cause a reduction in cytochrome C mediated apoptosis.22 Previous studies have demonstrated that 
SLC-39A6 expression is induced by estrogen.23  SLC-39A6 gene expression was also found to be 
significantly higher in breast tumors compared to normal mammary epithelium. Importantly, SLC-
39A6 protein expression was correlated with lower grade tumors of smaller size. Patients with ER 
positive breast cancer expressing high levels of SLC-39A6 had longer relapse free survival (RFS) 
when compared to other patients in the cohort. This correlation was also observed at the protein 
level.24  We are interested in seeing if SLC-39A6 plays a tumor suppressor role in the context of 
endocrine therapy. A reduction in SLC-39A6 may thus promote cell survival in TAM or FAS 
resistant cells. However, the tumor suppressor role of SLC-39A6 is not consistent among other 
cancers. In liver cancer cells, downregulation of SLC-39A6 repressed cell growth.25 In esophageal 
squamous cell carcinoma (ESCC), SLC-39A6 protein expression was correlated with shorter length 
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of survival in patients with advanced ESCC.26 Interestingly, one member of the SLC family of 
transporters, SLC22 is a known transporter of cisplatin and oxaliplatin.27 It is possible that SLC-39A6 
could be a transporter of TAM or FAS, and its repression may therefore reduce the efficacy of TAM 
or FAS. While it seems that patients with increased SLC-39A6 expression have better disease 
outcome in breast cancer, the role of SLC-39A6 in the development of breast cancer remains elusive 
and warrants further study. 
SIGNIFICANCE 
 Endocrine therapy is the most effective therapy for estrogen receptor positive (ER+) breast 
cancer patients and thus resistance to endocrine therapy is an unfortunate reality for many of these 
patients.  There are very few options and no additional approved targeted therapy for the patients who 
develop resistance to endocrine therapy. Our study has identified several novel genes that are either 
up or downregulated when the GLI-1 transcription factor was ectopically expressed in MCF7 cells. It 
is expected that detailed analysis of these genes will uncover pathways that promote resistance and 
provide additional targets for future therapy. The impact of this study is three fold:  
1) This study will identify novel Hhg target genes that are regulated by the transcription factor, 
GLI-1.  
2) It is important to note that GLI-1 is a known activator of transcription and not an inhibitor. 
This study could also elucidate a novel repressive role of GLI-1.   
3) This study could delineate the role of novel Hhg target genes in endocrine resistance that in 
the future could be therapeutically targeted to improve patient outcome. 
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HYPOTHESIS 
 As our previous study demonstrated the importance of GLI-1 in tamoxifen resistance, we 
hypothesize that GLI-1 reduces sensitivity to endocrine therapy by upregulating or downregulating 
target genes that inhibit apoptosis, drug influx, or other cell death mechanisms. We also hypothesize 
that GLI-1 can act as a transcriptional repressor by binding alone or with other proteins to the GLI-1 
consensus sequences on the promoter of putative target genes. Specifically, we will investigate the 
role of GLI-1 in regulation of SLC-3A96 and its potential tumor suppressor role.  
 
SPECIFIC AIMS 
Specific Aim 1: Identify putative downstream targets of the transcription factor, GLI-1.  
Using MCF7 cells overexpressing GLI-1 (MCF7 GLI-1), we will perform gene expression analysis 
for 96 breast cancer-related genes.  This will lead to the identification of novel GLI-1 target genes 
and we expect to validate already identified GLI-1 targets.  
 
Specific Aim 2: Determine if A.GLI-1 directly represses SLC-39A6 by binding to its promoter and B. 
SLC-39A6 is involved in mediating the response to endocrine therapy. 
SLC-39A6 is one novel gene significantly downregulated in GLI-1 overexpressing cells. We 
plan to elucidate how GLI-1 represses SLC-39A6. If GLI-1 represses SLC-39A6 by directly binding 
to its promoter, this could shed light on a new regulatory mechanism of GLI-1. 
SLC-39A6 expression is directly correlated with longer RFS in breast cancer patients and 
inversely correlated with tumor size and grade. Downregulation of SLC-39A6 in the GLI-1 
overexpressing and endocrine resistant cells raises the probability that SLC-39A6 is involved in 
sensitizing the cells to endocrine therapy. 
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Specific Aim 3: Determine if GLI-1 correlates with the expression of putative target genes in breast 
cancer patients and if these targets are predictive of disease outcome. 
 We will look at the correlation between expression of GLI-1 and the putative target genes 
identified in specific aim 1 in ER+ breast cancer. We will also determine if combined expression of 
GLI-1 and its targets are better prognostic markers and correlate with disease recurrence. This data 
could also help design new combinatorial therapy targeting GLI-1 and its downstream effector genes.   
 
STUDY DESIGN 
Specific Aim 1: Identify putative downstream targets of the transcription factor, GLI-1. 
Using MCF7-GLI-1 and MCF7-vector cells we will compare expression of 96 breast cancer-
related genes by PCR-based microarray analysis. Expression of newly identified genes will be 
validated by real-time PCR in these two cell lines. In addition, expression of these genes will be 
determined in MCF7 parental cells and MCF7 cells resistant to tamoxifen (TAM-R) and faslodex 
(FAS-R).  
 
Specific Aim 2 A. Determine if GLI-1 represses SLC-39A6 by directly binding to the promoter.  
The SLC-39A6 promoter will be analyzed using the rVista software (http://rvista.dcode.org) 
for putative GLI-1 binding sites. Human SLC-39A6 promoter spanning three putative GLI-1 binding 
sites will be cloned into the pGL3 luciferase reporter vector. MCF7-GLI-1 and MCF7-vector cells 
will be transfected with this plasmid along with Renila-Luciferase vector (Promega) as an internal 
control. Luciferase activity will be measured using dual luciferase assays (Promega) and SLC-39A6 
promoter activity will be measured by firefly luciferase expression and normalized to  
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renilla luciferase expression. To assess the functional significance of the GLI-1 binding sites, each 
site will be individually mutated using Quik Change Lightening Site Directed Mutagenesis Kit 
(Agilent). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Specific Aim 2B) Determine if SLC-39A6 is involved in mediating the response to endocrine therapy
 To determine the effect of SLC-39A6 on tamoxifen and faslodex sensitivity, we will generate 
stable cell lines of MCF7 cells transduced with sh-SLC-39A6 shRNA. We will monitor the cytotoxic 
effects of tamoxifen and faslodex with MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium] 
cell viability assay. 
 
	  
Figure	  4.	  Promoter construct for SLC-39A6 A) pGL3 Basic reporter 
vector. B)SLC-39A6 and ERα promoter map showing putative GLI-1 
binding sites. Numbers indicate the distance in base pairs these putative 
sites are from the transcriptional start site. C)Wild-type and mutated 
sequences for the three putative GLI-1 binding sites.	  
Site% Wild%Type% Mutant%
!459% 5’!g%C%A%T%C%A%C%C%C%A%g!3’%
%
5’!g%G%A%T%A%A%A%C%A%C%g!3’%
%
!2097% 5’!g%G%T%C%C%T%C%C%C%A%g!3’%
%
5’!g%G%T%A%C%T%C%A%C%A%g!3’%
%
!3214% 5’!a%G%A%C%C%T%C%C%A%A%g%!3’%
%
5’!a%G%A%C%A%T%C%A%A%A%g%!3’%
%
A% B%
C%
15	  	  
 
Specific Aim 3: Determine if GLI-1 correlates with the expression of putative target genes in breast 
cancer patients and if these targets are predictive of disease outcome  
Patient data will be taken from the Hatzis data set where 298 ER+ patients were treated with 
tamoxifen for 5 years. Bioinformatic analysis will be handled by Steven Sizemore (Ohio State 
Comprehensive Cancer Center).  
 
MATERIALS & METHODS 
qPCR Array: The mRNA expression of 96 breast cancer related genes will be performed using PCR 
array from SABiosciences (Qiagen)  and total RNA isolated from MCF7-GLI-1 and MCF7-vector 
cells.  
Cell culture: Established MCF7 cell lines will be grown in phenol red containing containing DMEM 
(Sigma Aldrich) with 10% fetal bovine serum (FBS, Sigma Aldrich), non-essential amino acids 
(Cellgro), antibiotic/antimycotic, and 6ng/mL insulin (Complete DMEM). Tamoxifen (TAM-R) and 
faslodex resistant (FAS-R) cells were obtained from Dr. Kenneth P. Nephew (Indiana university) and 
will be cultured in their respective antiestrogen at different concentrations (100, 250, 500, and 1000 
nanomolar).28 Unless otherwise noted, the FAS-R and TAM-R cells used in this study will be 
cultured in 500 nM of the respective antiestrogen. Media without phenol red (phenol red free 
DMEM) will be supplemented with 10% charcoal-stripped FBS, antibiotic/antimycotic, 6ng/mL 
insulin, and 2mmol/L L-glutamine. 
RNA: Cells will be grown to 70-80% confluency, washed twice with PBS, and RNA will be isolated 
using Trizol (Life Technologies). cDNA will be made using High Capacity cDNA kit (Applied 
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Biosystems). Real-Time PCR will be preformed using SYBR Green PCR Master Mix (Applied 
Biosystems). 
Protein: Whole cell extracts will be prepared in SDS lysis buffer (1% SDS, 50mM Tris HCL, 10mM 
EDTA) and briefly sonicated. Proteins will be separated on SDS-PAGE gels and transferred to PVDF 
membrane. Blots will be blocked for 30 minutes in 0.1% TBST and 5% milk and incubated overnight 
with primary antibody. Blots will be reprobed with GAPDH antibody and incubated for one hour. 
This will be followed by incubation with anti-rabbit or anti-mouse secondary antibody for one hour 
(GE Life Sciences) and developed using ECL reagent (Pierce). 
Antibodies: SLC-39A6 rabbit polyclonal antibody (#042377, Sigma-Aldrich); Estrogen Receptor 
alpha mouse monoclonal (#066-100, Diagenode); GAPDH polyclonal antibody (#25778 Santa Cruz); 
EGFR (#1005, Santa Cruz); p-EGFR Y1068 (#2234s, Cell Signaling); ERK1-2 (#4695s, Cell 
Signaling); p-ERK1-2 (#4376s, Cell Signaling). 
Luciferase Assay: Cells will be seeded in 24-well plates in phenol red containing complete DMEM. 
The following day, cells will be transfected with100 ng of their respective pGL3 promoter-reporter 
vector (Promega) and the 1.0 ng pRLTK (thymidylate kinase promoter driven Renila Luciferase) as 
an internal control in DMEM with 5% FBS using Lipofectamine 2000 (Life Technologies). The 
following day, cells will be washed with 1x PBS and incubated in complete DMEM. Cells will be 
harvested 48 hours following transfection and promoter activity will be determined using the Dual 
Luciferase Reporter Assay kit (Promega) 
Bioinformatics:  Promoter sequence of SLC-39A6 will be obtained from the University of California 
at Santa Cruz (UCSC) genome browser. GLI-1 consensus binding sites will be located using rVista 
2.0 online transcription factor consensus sequence database (http://rvista.dcode.org). 
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Cloning & Mutations: The SLC-39A6 promoter will be amplified from MCF7 genomic DNA and 
ligated into the pGL3-Basic reporter vector. Mutations of the putative GLI-1 binding sites will be 
performed using QuikChange Lightning Site-Directed Mutagenesis Kit (Agilent Technologies) and 
verified by sequencing at The Ohio State University Nucleic Acid Core Facility. 
MTT Assay: Cells will be seeded in 96 well plates in phenol red free media. About 24 hours after 
seeding the cells will be starved overnight in 0.5% charcoal-stripped FBS containing PR-free DMEM. 
The next day, cells will be treated with 5µM tamoxifen or 5µM faslodex in the presence of 10nmol 
E2 for 72 hours. The drugs will be replenished after 48 hours. 
RESULTS 
 
Overexpression of GLI-1 in MCF7 cells leads to differential expression of several genes 
 As our previous study showed an increase in GLI-1 expression in tamoxifen resistant cells, we 
ectopically expressed GLI-1 in MCF7 cells and performed microarray analysis in order to determine 
putative GLI-1 targets. Overexpression of GLI-1 led to differential expression of several genes, 
shown in the heat map (Fig.5A) An increase in expression of several genes namely: IL-6, serpine-1, 
AR, EGFR, CCNE1, CSF1, ESR2, and ERBB2 was observed (Fig 5B).  Some of these genes, such as 
ABCG2, MYC, VEGF, SNAI2 were previously shown to be GLI1 target genes. These genes could be 
directly or indirectly regulated by GLI-1. Interestingly, several genes were markedly downregulated 
upon ectopic expression of GLI-1, namely: IGF1R, SLC-39A6, SLIT2, TFF3, THBS1, and PGR. 
(Fig. 5C). This led us to hypothesize that GLI-1 could have a direct repressive role on gene 
expression. 
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Validation of Putative GLI-1 Targets 
In order to validate the putative target genes of GLI-1, we analyzed expression of several 
upregulated and downregulated genes in MCF7 GLI-1 #1, MCF7 GLI-1 #2 clones (Fig. 6A & 7A, 
respectively). In addition, we also analyzed expression of these genes in MCF7 parental, FAS-R, and 
TAM-R cells (Fig 6B & 7B respectively). Several of the upregulated genes identified by the 
microarray demonstrated higher expression in both the GLI-1 overexpressing clones, TAM-R and 
FAS-R cells compared to MCF7-vector cells and parental MCF7 cells respectively. Similarly, we 
confirmed that several downregulated genes had reduced expression in the GLI-1 overexpressing 
cells and the endocrine resistant cells.  
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SLC-39A6 Protein is Reduced in MCF7 GLI-1, FAS-R, & TAM-R cells 
 As SLC-39A6 expression was correlated with better overall survival and disease free survival 
in ER+ patients and is downregulated in the resistant cells, we were interested in studying if loss of 
	  
	  
Figure 7. Validation of putative downregulated GLI-1 target genes with real time-PCR in A) 
MCF7 GLI-1 #1 & GLI-1 #2 cells and in B) MCF7 parental, FAS-R, and TAM-R cells. 	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this gene promotes endocrine resistance. As observed for mRNA expression, SLC-39A6 protein is 
also reduced in the MCF7 GLI-1 cells (Fig 8A), FAS-R, and TAM-R cells (Fig. 8B). 
 
 
SLC-39A6 Promoter Activity is Reduced in MCF7 GLI-1, FAS-R and TAM-R Cells 
 We hypothesized that SLC-39A6 was directly inhibited by GLI-1 binding to the promoter. 
Using rVista 2.0, we found three putative GLI-1 binding sites within 3.5kb upstream of the 
transcriptional start site. This region was cloned into the pGL3-Basic vector to determine  SLC39A6 
	  
 
Figure 8. Western blot analysis and quantification of SLC-39A6 protein normalized to GAPDH  
in A,C)MCF7-vector, GLI-1 #1, and GLI-1 #2 and B,D)MCF7 parental and TAM-R and FAS-R 
cells. Numbers indicate the concentration (nM) of antiestrogen that the cells are maintained in.  
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promoter activity.  Luciferase assay determined that the SLC-39A6 promoter activity was reduced in 
MCF7 GLI-1 cells (Fig. 9A) in addition to FAS-R and TAM-R cells (Fig. 9B). 
 
 
Mutation of Putative GLI-1 Binding Sites had no effect on SLC-39A6 Promoter Activity  
 Hypothesizing that GLI-1 may have a novel repressive role in the regulation of SLC-39A6 we 
mutated the three putative GLI-1 binding sites on the promoter. If GLI-1 is a direct negative regulator 
of gene expression, we expect an increase in SLC-39A6 promoter activity upon mutation of the GLI-
	  
Figure 9. SLC-39A6 promoter activity is reduced in A) MCF7 GLI-1 cells. Graph represents the 
fold change of promoter activity in MCF7 GLI-1 compared to vector control. B) FAS-R, and 
Tam-R cells. Graph represents the fold change of promoter activity in FAS-R &TAM-R cells 
compared to MCF7 parental cells.  In both assays, SLC-39A6 promoter-driven luciferase activity 
was normalized to pRLTK activity as an internal control.  
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Figure 10. Activity of the SLC-39A6 promoter in MCF7 GLI-1 #1 cells, where putative GLI-1 binding site. 
A) at 459 base pairs and B) 1306 and 2944  base pairs upstream of transcription start site was mutated .  	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1 binding sites.  Mutation of all three sites: 459, 1306, and 2944 base pairs upstream of the TSS had 
no effect on the promoter activity (Fig. 10A & 10B). This suggested that GLI-1 does not act as direct 
repressor of SLC-39A6 and it is likely regulated through a different mechanism. 
Repression of SLC-39A6 does not increase FAS or TAM sensitivity 
  Hypothesizing that loss of SLC-39A6 promotes endocrine resistance in ER+ breast cancer, we 
knocked down SLC-39A6 protein in MCF7 cells and tested the resulting sensitivity to TAM or FAS.  
For this we expressed SLC-39A6 shRNA in MCF7 cells to mimic the SLC-39A6 loss observed in 
MCF7 GLI-1, FAS-R, and TAM-R cells. Western blot confirmed that SLC-39A6 expression was 
indeed reduced in this cell line (Fig. 11A). We then performed MTT assay with MCF7-vector and 
MCF7-sh-SLC-39A6 cells to compare the response of these cells to TAM and FAS (Fig. 11B). Cells 
were treated with DMSO (control), 5µM FAS, or 5µM TAM for 72 hours and cell viability was 
assessed. Although we expected the MCF7-sh-SLC-39A6 cells to be more sensitive to TAM and 
FAS, we did not observe any significant difference between MCF7-vector cells and MCF7-sh-SLC-
39A6 cells in their responses to endocrine therapy (Fig 11B). This suggests that SLC-39A6 does not 
play a role in mediating anti-estrogen sensitivity. 
 
 
 
 
	  
Figure	  11.	  Knockdown	  of	  SLC-­‐39A6	  does	  not	  increase	  FAS	  or	  TAM	  resistance	  in	  MCF7	  cells.	  A) Western blot showing knockdown of SLC-39A6 B) MTT assay of MCF7-vector and 
sh-SLC-39A6 cells treated with DMSO-only, 5µM FAS or 5µM TAM for 72 hours.  	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   B	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ERa expression is downregulated in GLI-1 overexpressing cells: 
As mutation of the GLI-1 binding sites on the SLC-39A6 promoter failed to alleviate the 
repressive effect of GLI-1 on SLC-39A6 promoter activity, we entertained the possibility that GLI-1 
is inhibiting ERα transcription and in turn down regulating ERα target genes. Analysis by real-time 
PCR showed significant decrease in ERα gene (ESR1) expression in MCF7-GLI-1 cells compared to 
the MCF7 –vector tor cells (Fig. 7A & 7B). Furthermore, previous studies have shown that ERα 
protein is reduced in GLI-1 overexpressing cells, supporting our observations.29 Our computational 
analysis revealed presence of several putative GLI-1 binding sites in the promoter region of ERα. We 
are in the process of cloning this region in pGL3 vector for further analysis.  
GLI-1 expression Correlates with expression of its Target Genes in Breast Cancer Patients 
 We next attempted to determine if expression of these novel GLI-1 target genes correlates 
with GLI-1 expression in primary human breast cancer. For this, we analyzed Hatzis data set that 
contains gene expression data of 298 ER+ breast cancer patients.30 We found a statistically 
significant correlation of GLI-1 expression with several upregulated and downregulated genes (Fig 
	  
Figure 12. GLI-1 mRNA correlates with mRNA expression with several putative 
genes obtained from the MCF7 GLI-1 microarray. A) Genes that positively correlate 
with GLI-1 B) Genes that negatively correlate with GLI-1. 	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12A, B). Interestingly, when ER+ patients were sub-grouped in Luminal A and Luminal B (that are 
usually Her2 positive) patients, the correlation is significant only in patients with Luminal A subtype 
of breast cancer. This data validates our microarray analysis and leads us to identify an important 
difference between Luminal A and B patients.   
Combined expression of GLI-1 and SNAI1 or EGFR is predictive of metastatic recurrence in the 
patients with Luminal A Breast Cancer 
 
 We next asked the question if combined expression of GLI-1 and its target genes have 
improved prognostic ability in ER+ patients compared to GLI-1 alone.  Our analysis revealed that 
GLI-1 along with SNAI1 (Fig 13A, p value= 0.0019) or EGFR (Fig. 13B, p value= 0.0065) are 
predictive of metastatic recurrence in patients with Luminal A subtype of breast cancer. Expression 
of GLI-1 alone or SNAI1 or EGFR was not predictive of metastatic recurrence in this patient 
population.  
 
 
 
 
Figure 13. Kaplan-Meyer Curves predicting metastatic recurrence in patients with Luminal A breast cancer 
when GLI-1 expression is combined with A) SNAI1 and B) EGFR. 	  
!"##############$%&'()#*+"++,-.# /"##############$%&'()#*+"++01#
26	  	  
Expression And Phosphorylation Of EGFR Is Upregulated In MCF7-GLI-1 Cells  
 As expression of GLI-1 is significantly correlated with that of EGFR in Luminal A patients 
(Fig. 12A) and since patients with high GLI-1 and high EGFR  had  higher  probability  of metastatic 
recurrence (Fig. 13B) we were interested in the role of GLI-1 on EGFR expression and its activation. 
Western blot analysis showed upregulated EGFR protein in MCF7-GLI-1 cells compared to MCF7-
vector control (Fig. 14A). In addition, MCF7-GLI-1 cells had increased phosphorylated EGFR at 
tyrosine 1068 (Y1068) compared to MCF7-vector (Fig. 14A). Phosphorylated EGFR at Y1068 
demonstrates that EGFR is active and may be contributing to cell survival. The phosphorylation 
status of extracellular signal regulate kinases 1 and 2 (ERK-1-2), the downstream kinases commonly 
activated by EGFR was also assessed.  Our western blot analysis demonstrates that ERK1/2 are also 
increasingly phosphorylated in GLI1 overexpressing cells (Fig. 14B).  
 
 
 
 
 
 
 
 
 
 
 
 
 
	  
Figure 14. Total EGFR and phosphorylated EGFR are increased in MCF7-GLI-1 
compared to MCF7-vector controls. A) Basal level protein expression B) Protein 
expression and phosphorylation status with 48-hour starvation. 
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DISCUSSION 
          This study is a work in progress and we will continue to evaluate the role of the hedgehog 
pathway in regulating novel targets obtained from the PCR microarray and their importance in 
endocrine resistance. We examined the potential role of GLI-1 as a transcriptional repressor of the 
zinc transporter protein, SLC-39A6. As mutation of the putative GLI-1 binding sites failed to 
increase SLC-39A6 promoter activity, we expect GLI-1 suppresses SLC-39A6 in an indirect manner. 
This is most likely due to an inhibitory effect of GLI-1 on ERα. We observed a significant decrease 
in ERα gene expression in MCF7 GLI-1 cells. Furthermore, of the top six genes (IGF1R, SLC-39A6, 
SLIT2, TFF3, THBS1, PGR) that are maximally reduced in MCF7-GLI-1 cells (Fig. 3C), all were 
previously reported to be induced by estrogen treatment.  Treatment of breast cancer cell lines with 
estrogen led to the induction of IGF1R,31 SLC-39A632, and THBS1.33  Similarly, SLIT2 was shown 
to be induced by estrogen in the human endometrial Ishikawa cancer cell line34 and TFF3 was shown 
to be induced by E2 in endometrial adenocarcinoma cell lines.35 Although we did not validate 
downregulation of MUC1 and XBP1 in MCF7-GLI-1, TAM-R and FAS-R cells, it is important to 
note that MUC125 and XBP136, too, are regulated by ERα in Ishikawa endometrial and MCF7 breast 
epithelial cell lines, respectively. These data led us to believe that GLI-1 interferes with ERα 
expression. If GLI-1 activation is concurrent with loss in ERα expression or activity, this provides a 
plausible alternative mechanism for endocrine resistance. It is expected that repression of ERα and 
activation of an alternative survival mechanism (Hedgehog pathway), that is not a target of anti-
estrogenic compounds will reduce the efficacy of TAM or FAS and increase resistance to endocrine 
therapy. (Fig 15)
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We also investigated the role of SLC-39A6 in increasing sensitivity to endocrine therapy. Our 
study did not suggest that SLC-39A6 plays any significant role in sensitizing the cells to TAM or 
FAS. Although previous studies demonstrated SLC-39A6 is associated with better disease free 
survival, it appears to be a marker of functional ERα in the cells.  More studies are warranted to 
understand the role of this protein in breast carcinogenesis. 
 Importantly our bioinformatic analysis revealed a strong correlation between expression of 
GLI-1 and putative target genes in ER+ patients. Among the ER+ patients, Luminal A subtypes are 
expected to perform better on endocrine therapy compared to Luminal B patients. However there is a 
subpopulation of Luminal A patients that fail to respond to anti estrogenic compounds and the reason 
for such failure is largely unknown.3 Our bioinformatic analysis correlating GLI-1 with SNAI1 and 
EGFR in the prediction of worse metastatic recurrence in breast cancer patients with Luminal A 
subtype provides a plausible cause for failure of endocrine therapy. It is conceivable that de novo or 
drug inducible activation of Hedgehog pathway in ER + breast cancer is one of the key mechanisms 
how these cancer cells fail to respond to anti-estrogenic compounds.   
Figure 15. Possible mechanism of resistance through downregulation of ERα. A) When ERα is 
present, TAM binds to ERα and causes cell death. B) In the absence of ER (or functional ERα) there 
is no substrate for TAM, and therefore therapy is not effective. The cells are no longer targetable by 
anti-estrogenic compound and evade cell death. 
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Along with increased expression of EGFR in GLI-1 overexpressing MCF7 cells, our studies 
also eluded to increased phosphorylation of EGFR and its down stream gene ERK1/2. Based on this 
observation we believe that therapeutic targeting of GLI-1 and EGFR could be a potential option for 
patients with Luminal A breast cancer who fails endocrine therapy. Importantly, several EGFR 
inhibitors like Gefitinib and Erlotinib are approved for human trials. Currently there is a phase one 
clinical trial using therapies that target both SMO and EGFR in patients with metastatic pancreatic 
cancer.10  
All of the hedgehog pathway inhibitors approved for therapy or in clinical trials target and 
inhibit SMO. However, one study showed that GLI-1 is activated by mechanisms that are not reliant 
on SMO activation. For example, the cytokine osteopontin (OPN) was shown to increase GLI-1 
transcription even in the presence of SMO inhibitors. This alternative pathway is likely to render 
SMO targeted therapy ineffective.37 In a medulloblastoma patient, an acquired SMO mutation 
rendered the patient refractory to the SMO inhibitor, Vismodegib.38 Therefore, as an alternative to 
SMO targeting it is expected that developing GLI-1 inhibitors will be beneficial for such patients. 
This will directly target the protein that is ultimately responsible for genomic regulation and drug 
resistance in many types of cancers. Developmental and preclinical studies along this line are in 
progress.  
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